スタッフ紹介

助教北潟谷　隆

Takashi Kitagataya

助教　北潟谷　隆

学歴

2008年3月
北海道札幌南高等学校　卒業
2014年3月
北海道大学医学部医学科　卒業
2022年9月
北海道大学大学院医学研究院医学専攻博士課程　終了

職務経歴

2014年4月
製鉄記念室蘭病院　初期研修医
2016年4月
北海道医療センター　消化器内科　医員
2017年4月
市立函館病院　消化器内科　医員
2018年4月
苫小牧市立病院　消化器内科　医員
2019年4月
北海道大学病院　消化器内科　医員
2022年4月
Research fellow, Gastroenterology and Hepatology Department, Mayo Clinic
2023年7月
北海道大学病院　消化器内科　特任助教

所属学会・資格

  • 日本内科学会　総合内科専門医
  • 日本消化器病学会　消化器病専門医　北海道支部評議員
  • 日本消化器内視鏡学会　消化器内視鏡専門医
  • 日本肝臓学会　肝臓専門医
  • 日本肥満学会
  • 日本門脈圧亢進症学会

受賞歴・研究助成歴

＜研究助成＞

  • 日本学術振興会　科学研究費助成事業
    若手研究「肝細胞癌におけるLSECtin/LAG-3 axisとがん微小環境の関連性の検討と臨床応用」研究代表者（R6年度-R8年度）

＜受賞歴＞

  • 2016年11月　第278回日本内科学会北海道地方会最優秀若手奨励賞（後期研修医の部）
  • 2025年5月　 EASL Congress 2025 Young Investigator Award
  • 2026年4月 　APASL Oncology 2026 Tokyo Young Investigator Award
  • 2026年6月　 日本肝臓学会　研究奨励賞

業績
（英文のみ）

  1. Tsunematsu S, Muto S, Oi H, Naka T, Kitagataya T, Sasaki R, Taya Y, Baba U, Tsukamoto Y, Uemura K, Kimura T, Ohara Y.
    Surgically diagnosed primary hepatic angiosarcoma.
    Intern Med. 57, 687-691, 2018.
  2. Naruse H, Shimoyama N, Kudo T, Yamamoto Y, Hatanaka K, Ohno M, Itoh J, Shimoda Y, Kitagataya T.
    A case of mixed adenoneuroendocrine carcinoma of the distal bile duct.
    Nihon Shokakibyo Gakkai Zasshi. 115, 544-553, 2018.
  3. Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N.
    High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
    Hepatol Res. 50, 671-681, 2020.
  4. Kitagataya T,* Suda G,* Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N.
    Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    J Gastroenterol Hepatol. 35, 1782-1788, 2020.
  5. Suda G, Ogawa K, Kimura M, Maehara O, Kitagataya T, Ohara M, Tokuchi Y, Kubo A, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Sakamoto N.
    Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
    Hepatol Res. 50, 1196-1200, 2020.
  6. Shigesawa T, Suda G, Kimura M, Shimazaki T, Maehara O, Yamada R, Kitagataya T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.
    JGH Open. 4, 880-888, 2020.
  7. Nakai M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Ohara M, Umemura M, Sho T, Morikawa K, Ogawa K, Sakamoto N.
    Durable response without recurrence to Tolvaptan improves long-term survival.
    J Gastroenterol. 55, 1150-1161, 2020.
  8. Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N.
    Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Carcinogenesis. 42, 58-69, 2021.
  9. Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J Gastroenterol. 56, 168-180, 2021.
  10. Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    PLoS One. 16, e0247728, 2021.
  11. Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N.
    Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
    Sci Rep. 11, 9207, 2021.
  12. Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J Viral Hepat. 28, 755-763, 2021.
  13. Yoshida S, Suda G, Ohara M, Fu Q, Yang Z, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Maehara O, Ohnishi S, Sakamoto N.
    Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
    Nutrients. 13, 2415, 2021.
  14. Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
    Cancers (Basel). 13, 3633, 2021.
  15. Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohara M, Yamada R, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
    Sci Rep. 11, 16616, 2021.
  16. Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.
    Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
    Hepatol Res. 51, 979-989, 2021.
  17. Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N.
    Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
    World J Gastrointest Oncol. 13, 2076-2087, 2021.
  18. Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Cancers (Basel). 14, 232, 2022.
  19. Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 17, e0261760, 2022.
  20. Nakai M, Yamamoto Y, Baba M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Sho T, Morikawa K, Ogawa K, Furuya K, Sakamoto N.
    Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
    Sci Rep. 12, 1449, 2022.
  21. Takimoto-Sato M, Miyauchi T, Suzuki M, Ujiie H, Nomura T, Ikari T, Nakamura T, Takahashi K, Matsumoto-Sasaki M, Kimura H, Kimura H, Matsui Y, Kitagataya T, Yamada R, Suzuki K, Nakamura A, Nakai M, Sho T, Ogawa K, Sakamoto N, Yamaguchi N, Otsuka N, Tomaru U, Konno S.
    Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia.
    Front Genet. 13, 870192, 2022.
  22. Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, Ando S, Shimazaki T, Izumi T, Umemura M, Kitagataya T, Shigesawa T, Suzuki K, Kimura M, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Ohnishi S, Sugiyama T, Takeda H, Sakamoto N.
    The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
    Hepatol Res. 52, 508-521, 2022.
  23. Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M, Mizokami M, Sakamoto N.
    Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
    Hepatol Res. 52, 586-596, 2022.
  24. Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.
    Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
    Hepatol Res. 52, 603-613, 2022.
  25. Nakai M, Suda G, Ogawa K, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Ohara M, Sho T, Morikawa K, Sakamoto N.
    Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    PLoS One. 17, e0270786, 2022.
  26. Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N.
    Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma.
    World J Hepatol. 14, 1480-1494, 2022.
  27. Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N.
    Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
    Cancers (Basel). 14, 3938, 2022.
  28. Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N.
    Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    J Viral Hepat. 29, 976-985, 2022.
  29. Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Hosoda S, Tokuchi Y, Kitagataya T, Ohara M, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
    Viruses. 15, 181, 2023.
  30. Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N.
    Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
    Cancers (Basel). 15, 593, 2023.
  31. Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N.
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 95, e28452, 2023.
  32. Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.
    Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
    Liver Cancer. 12, 156-170, 2023.
  33. Kohya R, Suda G, Ohara M, Sasaki T, Yoda T, Sakurai N, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
    Cancers (Basel). 15, 3257, 2023.
  34. Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
    Hepatol Res. 53, 595-606, 2023.
  35. Nakai M, Morikawa K, Sasaki T, Kohya R, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N.
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 58, 656-667, 2023.
  36. Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, Yoda T, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Komukai S, Ogawa K, Sakamoto N.
    Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
    Hepatol Res. 53, 960-967, 2023.
  37. Ohara M, Suda G, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.
    Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
    Front Nutr. 10, 1272728, 2023.
  38. Krishnan A, Ozturk NB, Cutshaw KA, Guicciardi ME, Kitagataya T, Olson KE, Pavelko KD, Sherman W, Wixom AQ, Jalan-Sakrikar N, Baez-Faria M, Gutierrez F, Gores GJ.
    Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) deletion in myeloid cells augments cholestatic liver injury.
    Sci Rep. 14, 2145, 2024.
  39. Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, Kobayashi T, Takagi T, Sakamoto N.
    Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Target Oncol. 19, 769-778, 2024.
  40. Yasuura N, Suda G, Ohara M, Meno A, Sho T, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Saitou T, Sugiyama M, Fukuhara T, Baba M, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Taketomi A, Sakamoto N.
    Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
    Aliment Pharmacol Ther. 60, 1315-1324, 2024.
  41. Yang Z, Suda G, Sho T, Maehara O, Ohara M, Yoda T, Fu Q, Sasaki T, Kohya R, Yoshida S, Hosoda S, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Ohnishi S, Yamamoto Y, Baba M, Yamada R, Kobayashi T, Chen M, Sakamoto N.
    Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
    Hepatol Res. 55, 433-443, 2025.
  42. Kohya R, Suda G, Ohara M, Hosoda S, Sho T, Chuma M, Komori A, Kugiyama Y, Yasui Y, Tsuchiya K, Kurosaki M, Tani J, Kaneko S, Nakagawa M, Asahina Y, Maekawa S, Enomoto N, Yamamoto Y, Baba M, Yamada R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Sakamoto N.
    Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
    JHEP Rep. 7, 101364, 2025.
  43. Ohara M, Suda G, Kohya R, Yasui Y, Tsuchiya K, Kurosaki M, Tani J, Maekawa S, Enomoto N, Chuma M, Morimoto M, Kaneko S, Nakagawa M, Asahina Y, Komori A, Kugiyama Y, Baba M, Nakamura A, Ito J, Yamada R, Hosoda S, Yamamoto Y, Yoshida S, Sho T, Sasaki T, Yoda T, Meno A, Yasuura N, Fu Q, Yang Z, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Ogawa K, Sakamoto N.
    Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Hepatol Int. 19, 1371-1381, 2025.
  44. Suda G, Sugiyama M, Hikita H, Nishio A, Tatsumi T, Takehara T, Murakawa M, Nakagawa M, Asahina Y, Mizokami M, Kakisaka T, Sakamoto Y, Taketomi A, Miyanishi K, Ueno Y, Haga H, Maekawa S, Enomoto N, Kurosaki M, Kohjima M, Nakamuta M, Tanaka Y, Yamamoto Y, Baba M, Hanamatsu H, Furukawa JI, Ohara M, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ogawa K, Sakamoto N.
    Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
    Biomark Res. 13, 113, 2025.
  45. Kitagataya T, Suda G, Tanaka T, Kitano S, Yasuura N, Meno A, Sasaki T, Kohya R, Fu Q, Hosoda S, Yoshida S, Maehara O, Ohnishi S, Ohara M, Nakai M, Sho T, Nakamura K, Ishizaka S, Sakamoto N.
    Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
    Hepatol Res. 55, 1367-1375, 2025.
  46. Suda G, Baba M, Yamamoto Y, Yoshida S, Muranaka T, Meguro T, Terashita K, Ito J, Kobayashi T, Izumi T, Takagi T, Hosoda S, Yamada R, Fu Q, Yang Z, Yokoyama D, Tanaka T, Meno A, Yasuura N, Kitagataya T, Ohara M, Kawagishi N, Nakai M, Sho T, Ogawa K, Sakamoto N.
    Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
    Sci Rep. 15, 42628, 2025.
  47. Kitagataya T, Krishnan A, Olson KE, Gutierrez F, Baez-Faria M, Guicciardi ME, Pavelko KD, Azad AI, Gores GJ.
    Genetic ablation of interleukin-17A augments fibrosis in a mouse model of cholestatic liver injury.
    PLoS One. 21, e0342251, 2026.
  48. Tanaka T, Suda G, Ohara M, Maehara O, Yoda T, Fu Q, Yang Z, Yasuura N, Meno A, Sasaki T, Kohya R, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ohnishi S, Sakamoto N.
    Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
    Front Nutr. 13, 1730695, 2026.
  49. Nakai M, Ohara M, Yokoyama D, Kitano S, Tanaka T, Yasuura N, Meno A, Kitagataya T, Sho T, Suda G, Sakamoto N.
    Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.
    Hepatol Res. 56, 505-514, 2026.
  50. Suda G, Ohara M, Baba M, Yamamoto Y, Yoshida S, Fu Q, Yang Z, Hosono H, Yokoyama D, Kitano S, Tanaka T, Meno A, Yasuura N, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ogawa K, Maehara O, Ohnishi S, Izumi T, Yamada R, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N.
    Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.
    J Infect. 92, 106715, 2026.
  51. Tanaka T, Suda G, Ohara M, Yokoyama D, Kitano S, Maehara O, Yoda T, Fu Q, Yang Z, Yasuura N, Meno A, Sasaki T, Kohya R, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ohnishi S, Sakamoto N.
    Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
    J Cachexia Sarcopenia Muscle. 17, e70305, 2026.
  52. Yokoyama D, Suda G, Ohara M, Tanaka T, Kitano S, Maehara O, Deng R, Fu Q, Yang Z, Yasuura N, Meno A, Kohya R, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ohnishi S, Sakamoto N.
    HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.
    Virol J. 2026. (Epub ahead of print)
  53. Yasuura N, Suda G, Ohara M, Yokoyama D, Tanaka T, Meno A, Sho T, Kohya R, Deng R, Fu Q, Yang Z, Maehara O, Ohnishi S, Kitagataya T, Kawagishi N, Nakai M, Kakisaka T, Taketomi A, Sakamoto N.
    Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.
    J Gastroenterol. 2026. (Epub ahead of print)
  54. Meno A, Ohara M, Suda G, Sho T, Maehara O, Yasuura N, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohnishi S, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Sakamoto N.
    Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.
    Hepatol Int. 2026. (Epub ahead of print)